Profile data is unavailable for this security.
About the company
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.
- Revenue in CAD (TTM)0.00
- Net income in CAD-36.71m
- Incorporated2012
- Employees29.00
- LocationEupraxia Pharmaceuticals Inc201-2067 Cadboro Bay Rd.VICTORIA V8R 5G4CanadaCAN
- Phone+1 (250) 590-3968
- Fax+1 (250) 590-2588
- Websitehttps://eupraxiapharma.com/home/default.aspx
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Covalon Technologies Ltd | 29.20m | -823.40k | 85.21m | -- | -- | 3.71 | 677.67 | 2.92 | -0.0335 | -0.0335 | 1.18 | 0.8786 | 1.10 | 1.77 | 5.15 | -- | -3.11 | -18.06 | -3.72 | -27.10 | 56.45 | 51.89 | -2.82 | -27.06 | 3.72 | -21.12 | 0.0474 | -- | 46.56 | -0.096 | 51.79 | -- | 12.21 | -- |
Oncolytics Biotech Inc | 0.00 | -28.02m | 97.07m | 29.00 | -- | 5.29 | -- | -- | -0.3827 | -0.3827 | 0.00 | 0.2383 | 0.00 | -- | -- | -- | -87.53 | -81.99 | -101.45 | -97.25 | -- | -- | -- | -- | -- | -- | 0.0575 | -- | -- | -- | -11.75 | -- | -40.52 | -- |
Zentek Ltd | 35.31k | -11.10m | 107.19m | 25.00 | -- | 5.68 | -- | 3,035.59 | -0.1103 | -0.1103 | 0.0004 | 0.1813 | 0.0014 | 0.1621 | 0.1309 | 1,412.40 | -42.89 | -47.65 | -46.51 | -51.12 | -909.46 | -- | -31,439.08 | -13,980.33 | 1.54 | -- | 0.0558 | -- | -59.07 | -- | 18.80 | -- | -19.38 | -- |
Eupraxia Pharmaceuticals Inc | 0.00 | -36.71m | 137.26m | 29.00 | -- | 6.82 | -- | -- | -1.36 | -1.36 | 0.00 | 0.565 | 0.00 | -- | -- | 0.00 | -137.69 | -127.84 | -270.60 | -935.99 | -- | -- | -- | -- | -- | -- | 0.2545 | -- | -- | -- | -52.63 | -- | -7.69 | -- |
Medicenna Therapeutics Corp | 0.00 | -26.24m | 155.16m | 16.00 | -- | 6.78 | -- | -- | -0.374 | -0.374 | 0.00 | 0.2994 | 0.00 | -- | -- | 0.00 | -75.44 | -54.93 | -84.22 | -60.91 | -- | -- | -- | -- | -- | -2.29 | 0.00 | -- | -- | -- | -153.44 | -- | -- | -- |
NervGen Pharma Corp | 0.00 | -23.08m | 192.29m | 10.00 | -- | 15.37 | -- | -- | -0.3678 | -0.3678 | 0.00 | 0.1783 | 0.00 | -- | -- | -- | -101.90 | -121.15 | -227.88 | -180.20 | -- | -- | -- | -- | -- | -5.04 | 0.012 | -- | -- | -- | -8.01 | -- | 2.20 | -- |